drugset / Trial / NCT00626275

Study Evaluating the Analgesic Efficacy and Safety of ADL5859 in Participants With Rheumatoid Arthritis

NCT00626275

Phase 2 Completed 46 enrolled Merck & Co., Inc.
RandomizedCrossoverQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the effectiveness of ADL5859 in relieving pain associated with rheumatoid arthritis (RA) compared with placebo and naproxen (similar to Aleve®). A second objective is to see whether the effect of ADL5859 differs after a single dose compared with multiple doses.

Timeline

Start
2007-10
Primary completion
2008-09
Completion
2008-09

Drugs

EvaluationDrugModalityDoseRoute
Subject ADL5859 Small molecule 100 mg Oral
Subject ADL5859 Small molecule 200 mg Oral
Comparator Naproxen Small molecule 500 mg Oral

Indications